Table 1 Baseline characteristics and histologic outcomes of total patients

Age, mean ± SD, years

27 ± 8

31 ± 9

 < 0.001

Male, n, (%)

383(82.5)

203(87.1)

0.119

ALT, median (IQR), U/L

106 (40–300)

68 (28–231)

0.289

ALT ≤ ULN, n, %

117 (25.2)

92 (39.5)

ALT 1–2 × ULN, n, %

72 (15.5)

30 (12.9)

ALT ≥ 2 × ULN, n, %

275 (59.3)

111 (47.6)

AST, median (IQR), U/L

74 (38–172)

56 (32–137)

0.940

GGT, median (IQR), U/L

52 (25–109)

58 (32–124)

0.054

WBC, median(IQR), × 10⁹/L

6.1 (4.9–7.1)

5.9 (5.1–6.9)

0.377

PLT, median (IQR), × 10⁹/L

170 (137–205)

158 (128–197)

0.105

HBV DNA, median (IQR),

(log₁₀ copies/mL)^a

7.3 (6.1–8.3)

6.1 (4.9–7.0)

 < 0.001

Inflammation n (%)

0.096

 G0-1

78 (16.8)

54 (23.1)

 G2

192 (41.4)

92 (39.5)

 G3

135 (29.1)

60 (25.8)

 G4

59 (12.7)

27 (11.6)

Fibrosis n (%)

0.395

 S0-1

126 (27.2)

70 (30.0)

 S2

190 (40.9)

79 (33.9)

 S3

86 (18.5)

51 (21.9)

 S4

62 (13.4)

33 (14.2)